A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry

Shyr, 2020, Drug Discovery Strategies for SARS-CoV-2, J Pharmacol Exp Ther, 375, 127, 10.1124/jpet.120.000123 Chen, 2021, Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Frontiers in Pharmacology, 11, 10.3389/fphar.2020.592737 Tang, 2020, Coronavirus membrane fusion mechanism offers a potential target for antiviral development, Antiviral Res, 178, 10.1016/j.antiviral.2020.104792 Chen, 2020, Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles, ACS Pharmacology & Translational Science, 3, 1165, 10.1021/acsptsci.0c00112 Johnson, 2020, Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein, Journal of Virology, 94, e01062, 10.1128/JVI.01062-20 Jain, 2021, Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants, ACS Pharmacology & Translational Science, 4, 1675, 10.1021/acsptsci.1c00176 Sun, 2021, Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay, Bioorganic & Medicinal Chemistry, 38, 10.1016/j.bmc.2021.116119 Millet, 2019, Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting, J Vis Exp, e59010 Millet, 2016, Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection, Bio Protoc, 6, e2035, 10.21769/BioProtoc.2035 Xiao, 2021, A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent, Nature Structural & Molecular Biology, 28, 202, 10.1038/s41594-020-00549-3 Huang, 2019, The NCATS Pharmaceutical Collection: a 10-year update, Drug Discov Today, 24, 2341, 10.1016/j.drudis.2019.09.019 Wang, 2010, A grid algorithm for high throughput fitting of dose-response curve data, Curr Chem Genomics, 4, 57, 10.2174/1875397301004010057 Sun, 2010, Internalization and fusion mechanism of vesicular stomatitis virus and related rhabdoviruses, Future Virology, 5, 85, 10.2217/fvl.09.72 Kouznetsova, 2014, Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs, Emerg Microbes Infect, 3, e84, 10.1038/emi.2014.88 Zhang, 2009, Encyclopedia of Cancer, 3227, 10.1007/978-3-540-47648-1_6298 Nie, 2020, Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay, Nature Protocols, 15, 3699, 10.1038/s41596-020-0394-5 Zhang, 2020, Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro, Cell Discov, 6, 80, 10.1038/s41421-020-00222-5 Mediouni, 2021, Identification of Potent Small Molecule Inhibitors of SARS-CoV-2 Entry, bioRxiv Riva, 2020, Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing, Nature, 586, 113, 10.1038/s41586-020-2577-1 Elie, 2010, Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model, Biochimie, 92, 1618, 10.1016/j.biochi.2010.04.023 Satoyoshi, 1992, Therapeutic Trials on Progressive Muscular Dystrophy, Internal Medicine, 31, 841, 10.2169/internalmedicine.31.841 Tsujinaka, 1988, Synthesis of a new cell penetrating calpain inhibitor (calpeptin), Biochemical and Biophysical Research Communications, 153, 1201, 10.1016/S0006-291X(88)81355-X Takahashi, 2009, Characterization of CAA0225, a Novel Inhibitor Specific for Cathepsin L, as a Probe for Autophagic Proteolysis, Biological & Pharmaceutical Bulletin, 32, 475, 10.1248/bpb.32.475 Ikonomov, 2019, Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations, Toxicol Appl Pharmacol, 383, 10.1016/j.taap.2019.114771 Baranov, 2020, The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19, Cells, 10, 30, 10.3390/cells10010030 Hulseberg, 2019, Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses, J Virol, 93, e02185, 10.1128/JVI.02185-18 Hoffmann, 2020, Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature, 585, 588, 10.1038/s41586-020-2575-3 Peacock, 2021, SARS-CoV-2 one year on: evidence for ongoing viral adaptation, J Gen Virol, 102, 10.1099/jgv.0.001584